Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.
We report a primary squamous cell carcinoma of the prostate that developed in a 57-year-old man, 3 years after treatment with leuprolide and flutamide for Stage D1 adenocarcinoma of the prostate. This is the first case that describes this transformation from adenocarcinoma to squamous cell carcinoma following the use of luteinizing hormone agonists.
Braslis
K G
KG
Department of Urology and Pathology, University of Miami School of Medicine, Florida.
Davi
R C
RC
Nelson
E
E
Civantos
F
F
Soloway
M S
MS
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology*; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced*; D005485:Flutamide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology
D005485:Flutamide; D016729:Leuprolide